中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

22 records (took 0.025 seconds)

    ANTI-PRLR ANTIBODIES AND USES THEREOF
    1.
    发明申请
    ANTI-PRLR ANTIBODIES AND USES THEREOF 有权
    抗PRLR抗体及其用途

    公开(公告)号：US20150056222A1

    公开(公告)日：2015-02-26

    申请号：US14530265

    申请日：2014-10-31

    Applicant: Regeneron Pharmaceuticals, Inc.

    Inventor： Nicholas J. PAPADOPOULOS ,  Gavin THURSTON ,  Jessica R. KIRSHNER ,  Marcus P. KELLY ,  Thomas NITTOLI ,  Frank J. DELFINO ,  William C. OLSON ,  Yashu LIU

    IPC: A61K47/48 ,  C07K16/30 ,  C07K16/28

    CPC classification number: A61K47/48561 ,  A61K39/3955 ,  A61K47/48384 ,  A61K47/6803 ,  A61K47/6849 ,  C07K16/2869 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

    Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. According to certain embodiments, the invention includes antibodies that bind to the first fibronectin-like type III domain of the extracellular domain of PRLR. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders. The present invention also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent.

    Abstract translation: 本发明提供了结合催乳素受体（PRLR）的抗体及其使用方法。 根据某些实施方案，本发明的抗体以高亲和力结合人PRLR。 在某些实施方案中，本发明包括结合PRLR并阻断催乳素介导的细胞信号传导的抗体。 在其它实施方案中，本发明包括结合PRLR但不阻断催乳素介导的细胞信号传导的抗体。 根据某些实施方案，本发明包括结合PRLR细胞外结构域的第一纤连蛋白样III型结构域的抗体。 本发明的抗体可以是完全人抗体。 本发明包括与细胞毒性剂，放射性核素或对细胞生长或增殖有害的其它部分缀合的抗PRLR抗体。 本发明的抗体可用于治疗各种癌症以及其它PRLR相关疾病。 本发明还包括抗体药物缀合物，其包含特异性结合I类细胞因子受体的抗体或其抗原结合片段，其中所述抗体或其抗原结合片段与细胞毒性剂缀合。

    ANTI-PRLR ANTIBODIES AND USES THEREOF
    2.
    发明申请
    ANTI-PRLR ANTIBODIES AND USES THEREOF 有权
    抗PRLR抗体及其用途

    公开(公告)号：US20150056221A1

    公开(公告)日：2015-02-26

    申请号：US14464297

    申请日：2014-08-20

    Applicant: REGENERON PHARMACEUTICALS, INC.

    Inventor： Nicholas J. PAPADOPOULOS ,  Gavin THURSTON ,  Jessica R. KIRSHNER ,  Marcus P. KELLY ,  Thomas NITTOLI ,  Frank J. DELFINO

    IPC: A61K47/48 ,  A61K31/537 ,  C07K16/28

    CPC classification number: C07K16/2866 ,  A61K31/537 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2869 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94

    Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders. The present invention also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent.

    Abstract translation: 本发明提供了结合催乳素受体（PRLR）的抗体及其使用方法。 根据某些实施方案，本发明的抗体以高亲和力结合人PRLR。 在某些实施方案中，本发明包括结合PRLR并阻断催乳素介导的细胞信号传导的抗体。 在其它实施方案中，本发明包括结合PRLR但不阻断催乳素介导的细胞信号传导的抗体。 本发明的抗体可以是完全人抗体。 本发明包括与细胞毒性剂，放射性核素或对细胞生长或增殖有害的其它部分缀合的抗PRLR抗体。 本发明的抗体可用于治疗各种癌症以及其它PRLR相关疾病。 本发明还包括抗体药物缀合物，其包含特异性结合I类细胞因子受体的抗体或其抗原结合片段，其中所述抗体或其抗原结合片段与细胞毒性剂缀合。

    HUMAN ANTIBODIES TO PD-1
    4.
    发明申请
    HUMAN ANTIBODIES TO PD-1 审中-公开

    公开(公告)号：US20180185668A1

    公开(公告)日：2018-07-05

    申请号：US15905685

    申请日：2018-02-26

    Applicant: Regeneron Pharmaceuticals, Inc.

    Inventor： Nicholas J. PAPADOPOULOS ,  Andrew J. MURPHY ,  Gavin THURSTON ,  Ella IOFFE ,  Elena BUROVA

    IPC: A61N5/10 ,  C07K16/28 ,  A61K45/06 ,  A61K39/395 ,  A61K39/00

    Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.

Patent Agency Ranking